Ryan K. McBain, PhD, MPH; Andrew Dick, PhD; Mark Sorbero, MS; Bradley D. Stein, MD, PhD
Disclaimer: The findings and conclusions in this report are solely those of the authors. The study was deemed exempt by the RAND Institutional Review Board.
Financial Support: This study was supported by grants 5R01DA045800-02 and 5P50DA046351-02 from the National Institute on Drug Abuse, which had no role in the study's design, conduct, or reporting, apart from general oversight in accordance with National Institutes of Health guidelines.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-2403.
Reproducible Research Statement:Study protocol and statistical code: Available from Dr. McBain (e-mail, email@example.com). Data set: The Centers for Disease Control and U.S. Census Bureau data sets used in this analysis are publicly available.
McBain RK, Dick A, Sorbero M, et al. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007–2017. Ann Intern Med. 2020;:. [Epub ahead of print 7 January 2020]. doi: https://doi.org/10.7326/M19-2403
Download citation file:
Published: Ann Intern Med. 2020.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use